CURE Media Group’s Post

The size of the prostate is often compared to the size of a walnut, and the decision whether to screen begins with a conversation. In partnership with Cancer Council Australia and a multi-disciplinary expert advisory panel, Prostate Cancer Foundation of Australia has developed national evidence-based clinical practice guidelines on PSA testing and early management of test-detected prostate cancer. Find out more about the latest thinking in screening and when to discuss this with your patients: https://lnkd.in/gD_m9_yv

Targeted Versus Chemotherapy in Urothelial Cancer. A combination of an ADC and a ICI showed superior Progression free and Overall Survival ( almost doubled the survival Period) when compared to chemotherapy in advanced urothelial cancer. A true clinically meaningful benefit for this cancer. A treatment regimen (antibody–drug conjugate enfortumab vedotin, plus the immunotherapy pembrolizumab) had significant survival benefits over chemotherapy alone. This treatment has been given accelerated approval in the United States already, but this phase III trial confirms the potential benefits. This is an example of a drug combination being followed with a confirmatory clinical trial following accelerated approval. https://lnkd.in/gF-mG3sD

Adverse kidney outcomes of CDK 4/6 inhibitors for metastatic breast cancer Cyclin-dependent kinase (CDK) 4/6 inhibitors have significantly improved overall and progression free survival of patients with metastatic breast cancer, but their effect on short and long-term kidney function is unknown. We found that early, mild estimated glomerular filtration rate (eGFR) decline was common in patients treated with CDK 4/6 inhibitors; however, severe kidney injury is rare and long-term eGFR decline is uncommon. https://lnkd.in/deB9SDd6

The size of the prostate is often compared to the size of a walnut, and the decision whether to screen begins with a conversation. In partnership with Cancer Council Australia and a multi-disciplinary expert advisory panel, Prostate Cancer Foundation of Australia has developed national evidence-based clinical practice guidelines on PSA testing and early management of test-detected prostate cancer. This #prostatecancerawarenessmonth, find out more about the latest thinking in screening and when to discuss this with your patients: https://lnkd.in/gD_m9_yv

Lung cancer is the second most commonly diagnosed cancer worldwide. During #LungCancerAwarenessMonth, we are sharing key information about lung cancer testing. Did you know that current guidelines recommend: • Perioperative biomarker testing for all patients with stage IB-IIIA/B NSCLC • Considering both stage and known mutations/PD-L1 status when choosing between targeted therapy, chemotherapy, or immunotherapy as adjuvant treatment in early-stage NSCLC. NeoGenomics’ Early-stage NSCLC Panel is a therapy selection panel designed specifically for your early-stage NSCLC patients. To learn more, visit: https://lnkd.in/e4YX4RiC

Our approach to delivering next-generation #cancer treatments includes our expansive arsenal of modalities, such as immune cell engagers (ICEs), antibody-drug conjugates (ADCs) and targeted protein degraders. Our experts are leveraging these modalities and more to interfere with cancer processes, and target and eliminate cancer cells. Discover how we’re harnessing the potential of innovative anti-cancer modalities: https://bit.ly/3TIefu4

Join CURE and West Cancer Center & Research Institute on October 4th at 4:40 PM in Germantown, TN, for Educated Patient Updates in Metastatic Breast Cancer. Hear from experts like Dr. Gregory Vidal and connect with fellow patients and caregivers. Knowledge you'll walk away with includes: • Understanding metastatic breast cancer and its subtypes • Initial hormone therapy for treatment of ER+/HER2- metastatic breast cancer • Biomarkers: What they are and why we test for them • Next hormone therapy for ER+/HER2- metastatic breast cancer that progresses or stops responding • A hypothetical example of a patient’s treatment strategy Reserve your seat today: https://bit.ly/3sZQXGC

Despite recent advances in HER2-targeted therapy, there are major limitations to the currently available therapies, with some patients developing resistance and some types of HER2-positive disease not responding to conventional chemotherapy. The DIAmOND clinical trial has been developed by our researchers to identify a new immunotherapy treatment option for women and men with metastatic HER2 positive breast cancer. This research project not only aims to improve outcomes for patients with metastatic breast cancer but it will also investigate the side effects, safety and effectiveness of this new drug combination. Learn more: https://lnkd.in/g5WRzYp

While immune checkpoint inhibitors (ICI) have emerged as a useful treatment option for triple negative breast cancer, their effectiveness varies among patients. 📉 ❓How could we predict a patient's response before initiating treatment? In a collaboration with Exact Sciences, Genialis is presenting a poster that offers a more detailed view than the conventional PD-L1 biomarker. 💪 Meet Daniel Pointing at San Antonio Breast Cancer Symposium or stay tuned until next week to find out how our solution based on #machinelearning and #RNA-Seq data can benefit patients and their communities. 🤝 #SABCS23

Learn about the new treatments available for triple-negative breast cancer! Advances like antibody-drug conjugates and PARP inhibitors, are changing how breast cancer is treated. Watch this video to see these innovative therapies and how they can benefit your treatment. This knowledge will help empower you in your journey towards breast cancer treatment. Share this information and help raise awareness! https://ow.ly/WXWm50SARB8